Physician profile
Dimple Raina
NPI 1891918108
$11,345.16
in general payments reported to CMS, 2019-2025
41 companies · $2,900 in 2025
The $2,900 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,086 · 2020: $660 · 2021: $1,265 · 2022: $1,243 · 2023: $1,846 · 2024: $2,345 · 2025: $2,900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,055 · Education: $36.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,054.95 |
| Education | $36.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,106.92 | 2019-2025 | |
| Janssen Biotech, INC. | $1,134.88 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $771.80 | 2019-2025 | Entyvio, Gattex |
| Intercept Pharmaceuticals, INC. | $707.51 | 2019-2025 | Ocaliva |
| Genzyme Corporation | $537.85 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $481.37 | 2019-2025 | Xifaxan, Plenvu |
| Gilead Sciences, INC. | $414.24 | 2019-2025 | Livdelzi, Epclusa |
| Qol Medical, LLC | $407.22 | 2019-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $351.40 | 2023-2025 | Dupixent |
| Celgene Corporation | $293.98 | 2021-2023 | Zeposia |
| Pfizer INC. | $281.81 | 2023-2025 | |
| Madrigal Pharmaceuticals | $225.50 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Scientific Affairs, LLC | $225.00 | 2019-2022 | |
| Medtronic, INC. | $212.05 | 2023-2024 | Endoflip, Interstim, Gi Genius |
| Merck Sharp & Dohme LLC | $202.90 | 2019-2023 | Dificid |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dimple Raina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.